You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

venetoclax

Showing 26 - 50 of 319
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Lymphoblastic Leukemia Trial in New York (Venetoclax)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Venetoclax
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 2, 2023

Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder Trial in Boston (Pirtobrutinib, Venetoclax, Allopurinol)

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • B-Cell Lymphoproliferative Disorder
  • Boston, Massachusetts
  • +2 more
Feb 18, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in New York (Venetoclax, Tazemetostat)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • +2 more
  • New York, New York
    Weill Cornell Medicine/NewYork-Presberteryian Hospital
Jan 18, 2023

Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,

Not yet recruiting
  • Adenoid Cystic Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2023

Acute Myeloid Leukemia, MDS Trial (Cladribine, Cytarabine, Decitabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Mar 1, 2023

Richter Syndrome Trial in United States (Venetoclax, DA-EPOCH-R, R-CHOP)

Recruiting
  • Richter Syndrome
  • Venetoclax
  • +2 more
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

Lymphoma, Non-Hodgkin Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Vysis LSI MYC Break Apart Rearrangement

Recruiting
  • Lymphoma
  • +4 more
  • Vysis LSI MYC Break Apart Rearrangement Probe Kit
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)

Active, not recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Edmonton, Alberta, Canada
  • +1 more
Jan 31, 2023

AML, Adult Trial in Hangzhou, Shanghai, Wuhan (Selinexor, Azacitidine, Venetoclax)

Not yet recruiting
  • AML, Adult
  • Hangzhou, China
  • +3 more
Feb 12, 2023

HIV-1-infection Trial in Aarhus (Venetoclax)

Not yet recruiting
  • HIV-1-infection
  • Venetoclax
  • Aarhus, Denmark
    Aarhus University Hospital
Jan 5, 2023

MDS, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Aachen, Düsseldorf, Jena (Venetoclax, Amsacrine,

Not yet recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Venetoclax
  • +4 more
  • Aachen, NRW, Germany
  • +2 more
Mar 29, 2023

Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Trial in Tianjin (Vincristine, Daunorubicin, Cyclophosphamide)

Recruiting
  • Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Dec 13, 2022

Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse Trial in Miami (Bomedemstat,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Miami, Florida
    University of Miami
Dec 22, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 10, 2023

Hemophagocytic Lymphohistiocytosis Trial in Beijing (Venetoclax, Dexamethasone, Etoposide)

Recruiting
  • Hemophagocytic Lymphohistiocytosis
  • Venetoclax
  • +2 more
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Sep 15, 2022

Relapsed or Refractory Hematologic Malignancies Trial in Chicago (Omacetaxine, Venetoclax)

Recruiting
  • Relapsed or Refractory Hematologic Malignancies
  • Chicago, Illinois
    University of Illinois Cancer Center
Sep 27, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Pirtobrutinib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Nov 17, 2022

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Tianjin (Olverembatinib, Venetoclax, prednisone)

Recruiting
  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Oct 21, 2022

MDS, Myeloproliferative Chronic Myelomonocytic Leukemia Trial in Houston (Cladribine, Cytarabine, Venetoclax)

Recruiting
  • Myelodysplastic Syndromes
  • Myeloproliferative Chronic Myelomonocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta (Tocilizumab, Venetoclax)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Tocilizumab
  • Venetoclax
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 24, 2023

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Duarte, California
  • +2 more
Nov 10, 2022

Secondary Acute Myeloid Leukemia Trial in Ann Arbor (Venetoclax, FLAG Protocol)

Not yet recruiting
  • Secondary Acute Myeloid Leukemia
  • Venetoclax
  • FLAG Protocol
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Mar 22, 2023

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine, Navitoclax, Venetoclax)

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Duarte, California
    City of Hope Medical Center
Aug 15, 2022

Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome Trial in Columbus (Azacitidine, Quality-of-Life

Recruiting
  • Secondary Myelodysplastic Syndrome
  • Therapy-Related Myelodysplastic Syndrome
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Dec 1, 2022